Payment overview · 2025
General Payments
$1,811.62
110 reported records · 17 companies
Healthcare provider profile · identity verified
Samuel Thompson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, KY · NPI 1710483516
Verified facts
What the public records show
CMS Open Payments records show Samuel Thompson, MD received $1,811.62 in general payments during 2025 across 110 reported records.
Novo Nordisk Inc accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $391.66 | 21.6% | 24 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $221.85 | 12.2% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $216.43 | 11.9% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $202.36 | 11.2% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.84 | 8.5% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $137.53 | 7.6% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.24 | 5.1% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $68.20 | 3.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.51 | 3.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.90 | 2.6% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $45.52 | 2.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.74 | 2.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.04 | 1.9% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $34.04 | 1.9% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.87 | 1.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.28 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.61 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,811.62 | 110 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $202.36 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $193.60 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $165.18 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $164.58 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $154.75 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $153.84 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $153.84 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $143.66 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $124.75 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $104.59 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $100.24 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $100.24 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $68.20 | 4 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $55.81 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.87 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.90 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.99 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $45.52 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.83 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $12.78 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 127 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 61 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 80 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 222 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
80 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
222 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 416 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 304 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 101 |
| Losartan Potassium | Losartan Potassium | 260 | 94 |
| Lisinopril | Lisinopril | 259 | 94 |
| Ozempic | Semaglutide | 222 | 54 |
| Gabapentin | Gabapentin | 199 | 66 |
| Simvastatin | Simvastatin | 193 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 191 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 169 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 66 |
| Tramadol Hcl | Tramadol Hcl | 160 | 68 |
| Omeprazole | Omeprazole | 159 | 60 |
| Furosemide | Furosemide | 158 | 69 |
| Metformin Hcl | Metformin Hcl | 142 | 55 |
| Trazodone Hcl | Trazodone Hcl | 137 | 62 |
| Montelukast Sodium | Montelukast Sodium | 133 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 129 | 40 |
| Eliquis | Apixaban | 127 | 36 |
| Jardiance | Empagliflozin | 122 | 30 |
| Carvedilol | Carvedilol | 121 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 39 |
| Methylprednisolone | Methylprednisolone | 106 | 91 |
| Meloxicam | Meloxicam | 105 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 38 |
| Prednisone | Prednisone | 96 | 71 |
| Allopurinol | Allopurinol | 93 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 30 |
| Buspirone Hcl | Buspirone Hcl | 80 | 25 |
| Mounjaro | Tirzepatide | 80 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 29 |
| Xarelto | Rivaroxaban | 73 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 26 |
| Bumetanide | Bumetanide | 66 | 27 |
| Metformin Hcl Er | Metformin Hcl | 64 | 20 |
| Farxiga | Dapagliflozin Propanediol | 61 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 21 |
| Ezetimibe | Ezetimibe | 59 | 25 |
| Alprazolam | Alprazolam | 56 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 45 |
| Pregabalin | Pregabalin | 56 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 24 |
| Mirtazapine | Mirtazapine | 54 | 23 |
| Cefdinir | Cefdinir | 53 | 42 |
| Lorazepam | Lorazepam | 53 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 18 |
| Bupropion Xl | Bupropion Hcl | 52 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 21 |
| Memantine Hcl | Memantine Hcl | 52 | 17 |
| Spironolactone | Spironolactone | 52 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 19 |
| Benazepril Hcl | Benazepril Hcl | 51 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 19 |
| Alendronate Sodium | Alendronate Sodium | 49 | 15 |
| Doxepin Hcl | Doxepin Hcl | 49 | 17 |
| Glimepiride | Glimepiride | 49 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 20 |
| Rybelsus | Semaglutide | 48 | 15 |
| Azithromycin | Azithromycin | 47 | 43 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 15 |
| Sertraline Hcl | Sertraline Hcl | 46 | 19 |
| Finasteride | Finasteride | 45 | 17 |
| Synthroid | Levothyroxine Sodium | 44 | 18 |
| Celecoxib | Celecoxib | 42 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 30 |
| Famotidine | Famotidine | 39 | 14 |
| Meclizine Hcl | Meclizine Hcl | 39 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 31 |
| Nifedipine Er | Nifedipine | 38 | 14 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 18 |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 29 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Estradiol | Estradiol | 24 | 11 |
| Fenofibrate | Fenofibrate | 24 | 11 |
| Glipizide | Glipizide | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | 13 |
| Valacyclovir | Valacyclovir Hcl | 23 | 12 |
| Ramipril | Ramipril | 22 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 11 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | 11 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Nystatin | Nystatin | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,811.62 · 110 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, Azstarys, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, GEMTESA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, Symbravo, TRINTELLIX, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error